Versus Combination Therapy

HeierJS, Topping TM, Baumann W, et al. Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology 2000 107 2034. 

Berger WE, Fineman SM, Lieberman P, Miles RM. Double-bhnd trials of azelastine nasal spray monotherapy versus combination therapy with loratadine tablets and beclomethasone nasal spray in patients with seasonal allergic rhinitis. Rhinitis Study Groups. Ann Allergy Asthma Immunol 1999 82(6) 535-41. 

Jatoi A, Windshitl HE, Loprinzi CL, et al (2002) Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia. J Clin Oncol 20 567-573... 

Giamarellou H, Bassaris HP, Petrikkos G, et al. Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empirical therapy for granu-... 

Croce MA, Eabian TC, Stewart RM, Pritchard PE, Minard G, Trenthem L, Kudsk KA. Empiric monotherapy versus combination therapy of nosocomial pneumonia in trauma patients. J Trauma 1993 35 303-311. 

Kozlowski A, Charles SA, Harris JM (2001) Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 15 419 29 Krown SE, AeppU D, Balfour HH Jr (1999) Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 20 245-254 LaFleur DW, NardeUi B, Tsareva T, Mather D, Feng P, Semenuk M, Taylor K, Buergin M, Chinchilla D, Roshke V, Chen G, Ruben SM, Pitha PM, Coleman TA, Moore PA (2001) Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J Biol Chem 276 39765-39771... 

Moore RD, Wong WM et al (2000) Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea. AIDS 14(3) 273-278... 

Preclinical studies suggest mold-active azoles plus echinocandins have enhanced activity against Aspergillus A. terreus should be considered resistant to amphotericin B Activity of amphotericin B and voriconazole is decreased versus Aspergillus species higher doses or combination therapy may be indicated in more refractory cases... 

Combination therapy may provide improvement in longterm disease-free survival. The combination of fludarabine, cyclophosphamide, and rituximab improves CR rates compared with fludarabine alone (70% versus 20%) but at the expense of increased infections.28,29 Combinations of fludarabine and alemtuzumab are also being investigated, with the hope of improving overall survival.21... 

Jokela H, Dastidar P, Rontu R, Salomaki A, Teisala K, Lehtimaki T, Punnonen R (2003) Effects of long-term estrogen replacement therapy versus combined hormone replacement therapy on nitric oxide-dependent vasomotor function. J Clin Endocrinol Metab 88 4348-4354... 

Antipsychotics versus combined antipsychotic therapy and psychotherapy (five studies). Here, too, the results were clearly in favor of drug therapy because there were virtually no relevant differences between patients receiving antipsychotics alone and those treated with antipsychotics phis psychotherapy. Three of the five studies involved group therapy and the other two individual psychotherapy neither of these forms of psychosocial treatment augmented the effect of the simultaneously administered antipsychotics to any demonstrable extent. 

Psychotherapy versus combined psychotherapy and drug therapy (two studies). In both studies the patients received analytically orientated individual therapies with the result that the effect of the combined therapies was appreciably superior to that of psychotherapy alone. It was found in both studies that the administration of drugs had no unfavorable effect on... 

Sachs G, Bowden C, Chou J, et al. Risperidone versus placebo as combination therapy to mood stabilizers in the treatment of the manic phase of bipolar disorder focus on efficacy. Presented at the American Psychiatric Association Annual Meeting, Chicago, May 13-18, 2000. 

Paul M et al Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients Systematic review and meta-analysis of randomised trials. BM3 2004 328 668. [PMID 14996699]... 

Gerards AH et al Cyclosporine A monotherapy versus cyclosporine A and methotrexate combination therapy in patients with early rheumatoid arthritis A double blind randomised placebo controlled trial. Ann Rheum Dis 2003 62 291. [PMID 12634224]... 

Furlong NJ, Hulme SA, O Brien SV, Hardy KJ. Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy. Diabetes Care 2002 25(10) 1685-90. 

Tepes et al. reported the first clinical experience with abcix-imab and urokinase combination therapy in the peripheral circulation (44). Schweizer et al. used abciximab and rt-PA versus rt-PA with ASA in an 84 patient trial and found a significantly shorter duration of thrombolytic infusion was required to achieve lytic success in the combination group as well as improved clinical endpoints of less re-hospitalization, re-intervention, and amputation compared to ASA and heparin (45),... 

Duda et al. prospectively studied 70 patients in the PROMPT trial of UK and abciximab versus UK alone. The trial showed the combination therapy resulted in a decreased infusion time, improved amputation free survival, and improved open surgery free survival at 90 days (46). Interestingly, a post hoc economic analysis of the PROMPT trial found an economic benefit to combination therapy at 90 days based on endpoints of amputation free survival, survival without open surgery, lack of major amputation and lack of major complications. The extra cost of abciximab was more than offset by the decreased costs through improved patient outcomes (47). 

Vecchi M, Meucci G, Gionchetti P, Beltrami M, Di Maurizio P, Beretta L, Ganio E, Usai P, Campieri M, Fornaciari G, de Franchis R. Oral versus combination mesalazine therapy in active ulcerative colitis a doubleblind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther 2001 15(2) 251-6. 

Combination therapy with fluconazole (200 mg/day for 2 months) and flucytosine (150 mg/kg/day for the first 2 weeks n = 30) has been compared with fluconazole monotherapy (200 mg/day for 2 months n = 28) in a randomized open trial in Ugandan patients with AIDS-associated cryptococcal meningitis (12). Patients in both groups who survived for 2 months received maintenance therapy with fluconazole (200 mg three times per week for 4 months). There were no serious adverse events in any of the patients. The combination therapy prevented death within 2 weeks and significantly increased the survival rate at 6 months (32 versus 12%). However, the rate of positive cryptococcal antigen titers remained high at 2 months after treatment in both groups. 

---